Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21998656 | 0.84 | MAPK1 (0.56) | RAB9ASMN1; SMN2NPC1KMT2AMAPK1 | |
| SCHEMBL21998655 | 0.84 | MAPK1 (0.56) | RAB9ASMN1; SMN2NPC1KMT2AMAPK1 | |
| SCHEMBL21999368 | 0.84 | MAPK1 (0.56) | RAB9ASMN1; SMN2NPC1KMT2AMAPK1 | |
| SCHEMBL23001106 | 0.82 | HTT (0.46) | KMT2AMAPK1MEN1HTT | |
| SCHEMBL9549259 | 0.81 | FAAH (0.43) | RAB9AKMT2AMAPK1MEN1 | |
| SCHEMBL9549652 | 0.81 | FAAH (0.43) | RAB9AKMT2AMAPK1MEN1 | |
| SCHEMBL9549107 | 0.81 | FAAH (0.43) | RAB9AKMT2AMAPK1MEN1 | |
| Trimethylammonium SCHEMBL28144112 | 0.80 | MAPK1 (0.52) | RAB9ASMN1; SMN2NPC1KMT2AMAPK1 | |
| SCHEMBL6359808 | 0.80 | RAB9A (0.60) | RAB9ASMN1; SMN2NPC1KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL9549206 | 0.80 | FAAH (0.42) | RAB9AKMT2AMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | RAB9A 3510/4885SMN1; SMN2 623/4885NPC1 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.